Bio-Rad (BIO)

Executive Summary

Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics, offering a broad portfolio of instruments, consumables, and reagents. Founded in 1952 and headquartered in Hercules, California, the company serves customers worldwide, with particular strength in areas such as digital PCR, protein electrophoresis, and blood typing. Bio-Rad's long-standing reputation, diversified product base, and recurring revenue from consumables provide a stable financial foundation. The company's recent focus on expanding its clinical diagnostics offerings and digital biology platforms positions it for moderate growth in a competitive landscape. Despite macroeconomic headwinds, Bio-Rad's disciplined cost management and innovation pipeline support its resilience. With a market capitalization of approximately $7.6 billion, the company continues to invest in high-growth applications including liquid biopsy and infectious disease testing.

Upcoming Catalysts (preview)

• Q2 2026Launch of next-generation droplet digital PCR system85% success
• H2 2026FDA 510(k) clearance for a new clinical assay in infectious disease70% success
• Q2 2026Q1 2026 earnings report with revenue beat driven by consumables growth90% success